{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:11:45Z","timestamp":1781521905971,"version":"3.54.1"},"reference-count":44,"publisher":"The Fukushima Society of Medical Science","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FJMS","Fukushima J. Med. Sci."],"published-print":{"date-parts":[[2019]]},"DOI":"10.5387\/fms.2019-13","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T22:04:32Z","timestamp":1562105072000},"page":"25-29","source":"Crossref","is-referenced-by-count":1,"title":["Autoimmune hepatitis, fatty liver, and Fukushima"],"prefix":"10.5387","volume":"65","author":[{"given":"Atsushi","family":"Takahashi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Fukushima Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Ohira","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fukushima Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3342","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Takahashi H. Pathogenesis of Autoimmune Hepatitis. In: Autoimmune Liver Disease. Ohira H ed. Springer Japan, 3-20, 2014.","DOI":"10.1007\/978-4-431-54789-1_1"},{"key":"2","unstructured":"2. Onji M, Zeniya M, Yamamoto K, Tsubouchi H. Autoimmune hepatitis: Diagnosis and treatment guide in Japan, 2013. Hepatol Res, <b>44<\/b>: 368-370, 2014."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Manns MP, Czaja AJ, Gorham JD, <i>et al.<\/i> American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology, <b>51<\/b>: 2193-2213, 2010.","DOI":"10.1002\/hep.23584"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hegarty JE, Nouri Aria KT, Portmann B, Eddleston AL, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology, <b>3<\/b>: 685-689, 1983.","DOI":"10.1002\/hep.1840030510"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology, <b>4<\/b>: 622-627, 1984.","DOI":"10.1002\/hep.1840040409"},{"key":"6","unstructured":"6. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology, <b>35<\/b>: 890-897, 2002."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Yoshizawa K, Matsumoto A, Ichijo T, <i>et al.<\/i> Long-term outcome of Japanese patients with type 1 autoimmune hepatitis. Hepatology, <b>56<\/b>: 668-676, 2012.","DOI":"10.1002\/hep.25658"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Miyake Y, Iwasaki Y, Terada R, <i>et al.<\/i> Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol, <b>43<\/b>: 951-795, 2005.","DOI":"10.1016\/j.jhep.2005.06.006"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol, <b>102<\/b>: 1005-1012, 2007.","DOI":"10.1111\/j.1572-0241.2007.01153.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yokokawa J, Kanno Y, Saito H, <i>et al.<\/i> Risk factors associated with relapse of type 1 autoimmune hepatitis in Japan. Hepatol Res, <b>41<\/b>: 641-646, 2011.","DOI":"10.1111\/j.1872-034X.2011.00812.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Al-Chalabi T, Heneghan MA. Remission in autoimmune hepatitis: what is it, and can it ever be achieved? Am J Gastroenterol, <b>102<\/b>: 1013-1015, 2007.","DOI":"10.1111\/j.1572-0241.2007.01147.x"},{"key":"12","unstructured":"12. van Gerven NM, Verwer BJ, Witte BI, <i>et al.<\/i> Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol, <b>34<\/b>: 354-355, 2001."},{"key":"13","unstructured":"13. Takahashi A, Ohira H, Abe K, <i>et al.<\/i> Rapid corticosteroid tapering: Important risk factor for type 1 autoimmune hepatitis relapse in Japan. Hepatol Res, <b>45<\/b>: 638-644, 2015."},{"key":"14","unstructured":"14. Takahashi A, Arinaga-Hino T, Ohira H, <i>et al.<\/i> Autoimmune hepatitis in Japan: trends in a nationwide survey. J Gastroenterol, <b>52<\/b>: 631-640, 2017."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Onji M;Autoimmune Hepatitis Study Group.    Proposal of autoimmune hepatitis presenting with acute hepatitis, severe hepatitis and acute liver failure. Hepatol Res, <b>41<\/b>: 497, 2011.","DOI":"10.1111\/j.1872-034X.2011.00810.x"},{"key":"16","unstructured":"16. Nguyen Canh H, Harada K, Ouchi H, <i>et al.<\/i> Acute presentation of autoimmune hepatitis: a multicentre study with detailed histological evaluation in a large cohort of patients. J Clin Pathol, <b>70<\/b>: 961-969, 2017."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Harada K, Hiep NC, Ohira H. Challenges and difficulties in pathological diagnosis of autoimmune hepatitis. Hepatol Res, <b>47<\/b>: 963-971, 2017.","DOI":"10.1111\/hepr.12931"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yamamoto K, Miyake Y, Ohira H, <i>et al.<\/i> Prognosis of autoimmune hepatitis showing acute presentation. Hepatol Res, <b>43<\/b>: 630-638, 2013.","DOI":"10.1111\/j.1872-034X.2012.01109.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Zachou K, Arvaniti P, Azariadis K, <i>et al.<\/i> Prompt initiation of high-dose i.v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis. Hepatol Res, <b>49<\/b>: 96-104, 2019.","DOI":"10.1111\/hepr.13252"},{"key":"20","unstructured":"20. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology, <b>52<\/b>: 1836-1846, 2010."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Takahashi A, Abe K, Ohira H. Nonalcoholic Steatohepatitis-Autoimmune Hepatitis Overlap.    In: Autoimmune Liver Disease. Ohira H ed. Springer Japan, 127-136, 2014.","DOI":"10.1007\/978-4-431-54789-1_10"},{"key":"22","unstructured":"22. Hashida R, Kawaguchi T, Bekki M, <i>et al.<\/i> Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J Hepatol, <b>66<\/b>: 142-152, 2017."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Takahashi A, Abe K, Usami K, <i>et al.<\/i> Simple Resistance Exercise helps Patients with Non-alcoholic Fatty Liver Disease. Int J Sports Med, <b>36<\/b>: 848-852, 2015.","DOI":"10.1055\/s-0035-1549853"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Takahashi A, Imaizumi H, Hayashi M, <i>et al.<\/i> Simple Resistance Exercise for 24 Weeks Decreases Alanine Aminotransferase Levels in Patients with Non-Alcoholic Fatty Liver Disease. Sports Med Int Open, <b>1<\/b>: E2-E7, 2017.","DOI":"10.1055\/s-0042-117875"},{"key":"25","unstructured":"25. Moscatiello S, Di Luzio R, Bugianesi E, <i>et al.<\/i>    Cognitive-behavioral treatment of nonalcoholic Fatty liver disease: a propensity score-adjusted observational study. Obesity (Silver Spring), <b>19<\/b>(4): 763-770, 2011."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Seo SW, Gottesman RF, Clark JM, <i>et al.<\/i> Nonalcoholic fatty liver disease is associated with cognitive function in adults. Neurology, <b>6<\/b>: 1136-1142, 2016.","DOI":"10.1212\/WNL.0000000000002498"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Takahashi A, Kono S, Wada A, <i>et al.<\/i> Reduced brain activity in female patients with non-alcoholic fatty liver disease as measured by near-infrared spectroscopy. PLoS One, <b>12<\/b>: e0174169, 2017.","DOI":"10.1371\/journal.pone.0174169"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R. Association of obstructive sleep apnea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev, <b>14<\/b>: 417-431, 2013.","DOI":"10.1111\/obr.12020"},{"key":"29","unstructured":"29. Shen N, Wang P, Yan W. Sleep Duration and the Risk of Fatty Liver Disease: A Systematic Review and Meta-analysis. Sci Rep, <b>6<\/b>: 31956, 2016."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Imaizumi H, Takahashi A, Tanji N, <i>et al.<\/i> The Association between Sleep Duration and Non-Alcoholic Fatty Liver Disease among Japanese Men and Women. Obes Facts, <b>8<\/b>: 234-242, 2015.","DOI":"10.1159\/000436997"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. De Luca-Johnson J, Wangensteen KJ, Hanson J, Krawitt E,Wilcox R. Natural history of patients presenting with autoimmune hepatitis and coincident nonalcoholic fatty liver disease. Dig Dis Sci, <b>61<\/b>: 2710-2720, 2016.","DOI":"10.1007\/s10620-016-4213-3"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Takahashi A, Arinaga-Hino T, Ohira H, <i>et al.<\/i> Non-alcoholic fatty liver disease in patients with autoimmune hepatitis. JGH Open, <b>2<\/b>: 54-58, 2018.","DOI":"10.1002\/jgh3.12046"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Yasumura S, Hosoya M, Yamashita S, Fukushima Health Management Survey Group. Study protocol for the Fukushima Health Management Survey. J Epidemiol, <b>22<\/b>: 375-383, 2012.","DOI":"10.2188\/jea.JE20120105"},{"key":"34","unstructured":"34. Sakai A, Ohira T, Hosoya M, <i>et al.<\/i> White blood cell, neutrophil, and lymphocyte counts in individuals in the evacuation zone designated by the government after the Fukushima Daiichi Nuclear Power Plant accident: the Fukushima Health Management Survey. J Epidemiol, <b>25<\/b>: 80-87, 2015."},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Ohira T, Hosoya M, Yasumura S, <i>et al.<\/i> Effect of Evacuation on Body Weight After the Great East Japan Earthquake. Am J Prev Med, <b>50<\/b>: 553-560, 2016.","DOI":"10.1016\/j.amepre.2015.10.008"},{"key":"36","unstructured":"36. Ohira T, Hosoya M, Yasumura S, <i>et al.<\/i> Evacuation and Risk of Hypertension After the Great East Japan Earthquake: The Fukushima Health Management Survey. Hypertension, <b>68<\/b>: 558-564, 2016."},{"key":"37","unstructured":"37. Satoh H, Ohira T, Hosoya M, <i>et al.<\/i> Evacuation after the Fukushima Daiichi Nuclear Power Plant Accident Is a Cause of Diabetes: Results from the Fukushima Health Management Survey. J Diabetes Res, <b>2015<\/b>: 627390, 2015."},{"key":"38","unstructured":"38. Suzuki H, Ohira T, Takeishi Y, <i>et al.<\/i> Increased prevalence of atrial fibrillation after the Great East Japan Earthquake: Results from the Fukushima Health Management Survey. Int J Cardiol, <b>198<\/b>: 102-105, 2015."},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Hashimoto S, Nagai M, Fukuma S, <i>et al.<\/i> Influence of Post-disaster Evacuation on Incidence of Metabolic Syndrome. J Atheroscler Thromb, <b>24<\/b>: 327-337, 2017.","DOI":"10.5551\/jat.35824"},{"key":"40","unstructured":"40. Hayashi Y, Nagai M, Ohira T, <i>et al.<\/i> The impact of evacuation on the incidence of chronic kidney disease after the Great East Japan Earthquake: The Fukushima Health Management Survey. Clin Exp Nephrol, <b>21<\/b>: 995-1002, 2017."},{"key":"41","unstructured":"41. Satoh H, Ohira T, Nagai M, <i>et al.<\/i> Hypo-high-density Lipoprotein Cholesterolemia Caused by Evacuation after the Fukushima Daiichi Nuclear Power Plant Accident: Results from the Fukushima Health Management Survey. Intern Med, <b>55<\/b>: 1967-1976, 2016."},{"key":"42","unstructured":"42. Takahashi A, Ohira T, Hosoya M, <i>et al.<\/i> Effect of evacuation on liver function after the Fukushima Daiichi Nuclear Power Plant accident: The Fukushima Health Management Survey. J Epidemiol, <b>27<\/b>: 180-185, 2017."},{"key":"43","unstructured":"43. Takahashi A, Ohira T, Okazaki K, <i>et al.<\/i> Effects of lifestyle on hepatobiliary enzyme abnormalities following the Fukushima Daiichi nuclear power plant accident: The Fukushima health management survey. Medicine (Baltimore), <b>97<\/b>: e12890, 2018."},{"key":"44","unstructured":"44. Takahashi A, Ohira T, Uemura M, <i>et al.<\/i> Changes in Hepatobiliary Enzyme Abnormality After the Great East Japan Earthquake: The Fukushima Health Management Survey. Sci Rep, <b>7<\/b>: 710, 2017."}],"container-title":["FUKUSHIMA JOURNAL OF MEDICAL SCIENCE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/65\/2\/65_2019-13\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T03:43:31Z","timestamp":1567223011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/65\/2\/65_2019-13\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.5387\/fms.2019-13","relation":{},"ISSN":["0016-2590","2185-4610"],"issn-type":[{"value":"0016-2590","type":"print"},{"value":"2185-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}